File(s) under permanent embargo
Alternative targeted therapy for early HER2 positive breast cancer
journal contributionposted on 2013-02-01, 00:00 authored by S Harvey, Mustafa Khasraw
Her2 (erbB2) receptor is overexpressed in around twenty percent of early breast cancer and historically conferred a poorer prognosis (1). Targeted anti-Her2 therapy has significantly improved outcomes for these women.